AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 3, 2026, 4:30 PM ET Travere Therapeutics to Participate at Upcoming Investor Conferences Headline · Source: company release
Nasdaq: $TVTXRare kidney diseasesProduct sales, studies and licensing

TVTX Stock Hub: Travere Therapeutics News, FILSPARI and HARMONY

FILSPARI is the main source of Travere’s revenue growth. Its two U.S. kidney indications apply to different patient populations and establish different treatment claims. Travere is using the opportunity to support commercialization and invest in additional programs, including pegtibatinase and the newly licensed civorebrutinib.

Last updated: November 20, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
Travere Therapeutics ($TVTX), research updated November 20, 2026
18 pages on FILSPARI, HARMONY, licensing economics and convertible debt. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company-guided data window
Second half of 2027 · Expected HARMONY results

HARMONY’s primary measure is change in plasma total homocysteine from baseline, averaged across weeks 6 through 12.

Travere Therapeutics TVTX daily stock chart
Daily chart $TVTX. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts →

TVTX stock at a glance

Chart analysis · JC
Technical chart analysis of $TVTX with bull and bear scenarios on JC Just Charts.
Quarterly FILSPARI net sales
$200.192M
Quarterly new FILSPARI start forms
1,932
September cash and marketable securities
$471.818M
September convertible debt carrying amount
$603.510M
Continuing operating cash flow, nine months
$92.409M
October 28 common shares
95.992M

Where Travere Therapeutics stands now

Travere reported $200.192 million in third-quarter FILSPARI net product sales and 1,932 new patient start forms across IgA nephropathy and focal segmental glomerulosclerosis. The same quarter included $113.115 million in acquired in-process research and development expense for civorebrutinib. HARMONY enrollment continues, with initial results expected by the company in the second half of 2027. Commercial, accounting and clinical progress can be tracked independently. Travere Q3 SEC exhibit · Travere Form 10-Q

Constructive case

FILSPARI adoption and collections grow while the pipeline advances through specified study milestones.

Cautious case

Commercial investment grows faster than product cash generation and separate programs need more time.

Latest Travere Therapeutics news

Nov 3, 2026

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics announced it will participate at upcoming investor conferences. No further details were available in the source.

Nov 2, 2026

Travere Therapeutics Reports Third Quarter 2026 Financial Results

U.S. net product sales for the third quarter of 2026 were $220.2 million, compared to $113.2 million for the same period in 2025. FILSPARI U.S. net product sales totaled $200.2 million in the quarter, representing 120% growth year-over-year. The net loss for the third quarter of 2026 was $52.3 million, or $0.55 per basic share, compared to net income of $25.7 million, or $0.29 per basic share, for the same period in 2025. As of September 30, 2026, the Company had cash, cash equivalents, and marketable securities of $471.8 million.

Oct 26, 2026

Third-quarter results scheduled for November 2

Results are scheduled after the U.S. market close, followed by a conference call at 4:30 p.m. ET.

Oct 23, 2026

PROTECT biomarker data presented at ASN

The biomarker analysis compared FILSPARI with irbesartan over 110 weeks. Nominal p-values and changes in biomarkers do not establish clinical outcomes.

Oct 2, 2026

October 2: SPARTAN follow-up and a defined DUPLEX subgroup add evidence for ASN

Travere's October 2, 2026 release announces nine presentations, including five oral presentations, at ASN Kidney Week in Denver on October 21–25. It also discloses new results rather than merely scheduling a conference appearance. The two central datasets are the final two-year Phase 2 SPARTAN analysis in IgA nephropathy and a post hoc DUPLEX analysis in FSGS without nephrotic syndrome. They address different populations and study designs and do not add up to one efficacy claim.

Sep 23, 2026

USPTO allowance for an FSGS method-of-use patent

Application No. 19/253,120, directed to certain methods of using FILSPARI in FSGS, was allowed. Upon issuance it is expected to provide U.S. coverage into October 2037. The patent is not yet issued.

Catalyst calendar

  • April 13, 2026 · FDA approved FILSPARI to reduce proteinuria in the labeled FSGS population.
  • May 11, 2026 · 2032 convertible notes offering completed.
  • July 2026 · Everest license agreement closed.
  • November 2, 2026 · Third-quarter results.
  • December 1, 2026 · Scheduled effective date for the CEO transition.
  • Year end 2026 · Company plans U.S. civorebrutinib IND submission and anticipates first SPARLIGHT patient.
  • 2027 · Company anticipates SPARX data.
  • Second half of 2027 · Company target for HARMONY top-line data.

Travere Therapeutics deep dive: the full analysis

Explore the biotechnology research archive.

01 The contribution from kidney sales must support expanding investment

In the constructive case, more patients within the approved kidney indications begin and stay on therapy, sales conversion improves and the cost of supporting each additional patient becomes less burdensome to the business. Stronger operating cash generation might then support continued clinical investment. A positive HARMONY result would add a separate development opportunity. It would need to be evaluated on its own endpoints, patient population and manufacturing requirements. Travere Q3 update · HARMONY study registration

A middle case would have growing FILSPARI sales accompanied by continued spending on commercial infrastructure, clinical studies, manufacturing work and license commitments. That can produce expanding revenue and a less predictable GAAP operating result. Operating expenses, capitalized royalties and license payments help explain how sales growth translates into GAAP results and cash flow. Travere Form 10-Q, operating expenses and commitments

The cautious case combines weaker conversion of interest into paid prescriptions, more competition in IgA nephropathy, a slower launch in FSGS and a longer wait for programs that do not yet generate revenue. A narrower clinical result or additional manufacturing requirements could increase investment without adding an approved treatment. A commercial base concentrated in one product exposes the issuer to changes in prescribing, reimbursement and competing evidence. Travere Form 10-Q, product and operating risks

What would falsify this reading

The strongest test of the commercial thesis would be persistent growth in net sales and collections when the initial FSGS launch effect has had time to settle. A sustained divergence between new forms and subsequent sales would weaken the assumption that patient interest is turning into treatment. For the pipeline, a clearer answer requires actual study results and defined regulatory next steps. Continued increases in spending could alter the cash flow interpretation even if the market sees positive commercial milestones. Travere Form 10-Q, market outlook and cash flow

02 One drug has two claims with different evidence

The U.S. label describes sparsentan as a dual endothelin type A and angiotensin II type 1 receptor antagonist. The approved use in primary IgA nephropathy is to slow kidney function decline in adults at risk of disease progression. The label for focal segmental glomerulosclerosis, or FSGS, is to reduce proteinuria in adults and children aged eight years or older without nephrotic syndrome. The claims concern different endpoints and groups. Any comparison of the commercial opportunity needs to preserve those distinctions. FDA U.S. prescribing information

Proteinuria is excess protein in urine. The urine protein-to-creatinine ratio is one way clinical studies follow its change. Estimated glomerular filtration rate, or eGFR, describes a different property of the kidneys and can be followed as a slope over time. A treatment can have a measurable effect on one marker in a given study without demonstrating the same outcome on another. The prospect of health benefit depends on the study, the evidence available and the specific approved use. FDA label, clinical studies · Rheault et al., New England Journal of Medicine, 2023, DUPLEX

The November earnings release combines net sales and start forms for FILSPARI rather than showing separate revenue for each U.S. use. Increased aggregate revenue shows product growth and cannot separately establish the contribution from the FSGS launch. More specific measures, such as the pattern of new starts and continued treatment by indication, would help estimate the pace of penetration for each group. Travere Q3 SEC exhibit

03 PROTECT compared sparsentan with an active treatment

The Phase 3 PROTECT study in primary IgA nephropathy randomized participants to sparsentan or irbesartan. The prespecified interim analysis assessed the change in proteinuria at week 36. The use of irbesartan gave the investigators an active comparator rather than placebo. The long-term analysis assessed kidney-function slopes and whether the earlier proteinuria difference persisted. This design is important when comparing its outcome with other IgA nephropathy trials that used background care and a placebo control. Heerspink et al., The Lancet, 2023, interim report · Rovin et al., The Lancet, 2023, two-year report

At week 36, the reduction in urine protein-to-creatinine ratio was 49.8% with sparsentan and 15.1% with irbesartan. At week 110, the reduction in urine protein-to-creatinine ratio from baseline was 42.8% with sparsentan and 4.4% with irbesartan. The geometric least-squares mean ratio was 0.60, with a 95% confidence interval of 0.50 to 0.72, comparing the treatments. These are different ways of stating the on-study result. The ratio expresses the comparative result. The two baseline changes describe each group. An investor reviewing a later data release should check which of those quantities its claim refers to. Heerspink et al., The Lancet, 2023 · Rovin et al., The Lancet, 2023

The investigators also reported the chronic eGFR slope, measured after the early period of treatment, and the total slope, which included that early period. The chronic slope difference was 1.1 mL/min/1.73 m² per year (95% CI 0.1 to 2.1). The total slope difference was 1.0 mL/min/1.73 m² per year (95% CI −0.03 to 1.94). The distinction matters because a change seen early in therapy affects one analysis differently from the other. The approved U.S. IgA nephropathy indication concerns slowing decline in kidney function and is set out in the FDA label. Rovin et al., The Lancet, 2023 · FDA label

04 DUPLEX supports a narrower FSGS interpretation

DUPLEX randomized 371 people with FSGS without known secondary causes. The study compared sparsentan with irbesartan and followed participants for 108 weeks on treatment. The investigators used partial remission of proteinuria in the prespecified interim analysis and evaluated slope of eGFR as the primary efficacy endpoint at the final analysis. The proteinuria and eGFR findings answer separate questions. Rheault et al., New England Journal of Medicine, 2023, DUPLEX

At week 36, 42% of the sparsentan arm and 26% of the irbesartan arm met the proteinuria partial-remission endpoint. The published overall study did not show a significant difference in the primary final eGFR slope comparison. The FDA granted approval in April 2026 for reduction of proteinuria in people aged eight and older with FSGS without nephrotic syndrome. The approved population and claim are narrower than a general conclusion about slowing function decline in all forms of FSGS. Rheault et al., New England Journal of Medicine, 2023, DUPLEX · FDA approval notice

DUET, a shorter Phase 2 active-controlled study, also reported greater reductions in proteinuria with sparsentan. The randomized phase was followed by an open-label extension. The original and extension analyses each have a place in interpreting the development history. The shorter controlled comparison shows the measured effect at its time point and in its eligible sample. Follow-up after the controlled period can show what happened over longer use, with different limits on comparison. Trachtman et al., Journal of the American Society of Nephrology, 2018 · Campbell et al., Kidney Medicine, 2024

05 An approved indication still has operating constraints

The FDA label contains boxed warnings for hepatotoxicity and embryo-fetal toxicity. The restricted program described in the U.S. label addresses hepatotoxicity and entails baseline liver tests and monitoring every three months. The label addresses embryo-fetal toxicity with separate precautions. Enrollment in a sales-support process, medical eligibility and actual dispensing are therefore distinct milestones. The label also describes adverse reactions and restrictions that differ from the endpoints used to demonstrate efficacy. FDA U.S. prescribing information and REMS information

Travere has discussed post hoc results from patients without nephrotic syndrome in DUPLEX. At ASN Kidney Week it highlighted a post hoc comparison of 254 patients in that subgroup and reported week 108 mean reductions in urine protein-to-creatinine ratio of 48% with sparsentan and 27% with irbesartan. The analysis helps explain interest in the approved subgroup, but its retrospective status matters when considering outcomes beyond the labeled claim. Kidney failure counts or percentages in a subgroup with relatively few such events should not be treated as a separate trial designed to test that endpoint. Travere Q3 conference summary · FDA clinical and statistical review

The randomized DUPLEX study enrolled adults and children within the protocol criteria. A later published pediatric analysis reported a sustained proteinuria difference during follow-up. Its smaller dataset and the different distribution of clinical characteristics between age groups are relevant when reading detailed outcomes. Age eligibility on the label, the evidence from a pediatric subgroup and the total number of eligible patients are distinct. Rheault et al., Kidney International Reports, 2026 · FDA label

06 The IgA nephropathy market is changing around different evidence

The APPLAUSE-IgAN trial randomized adults with proteinuria despite supportive care to iptacopan or placebo. Its final 24-month analysis reported an annualized total eGFR slope of −3.10 with iptacopan and −6.12 with placebo, a difference of 3.02 mL/min/1.73 m² per year. The FDA’s July 2026 label for this use describes slowing kidney function decline in adults with primary IgA nephropathy at risk of progression. That is another available treatment pathway and a distinct monitored safety profile. Barratt et al., New England Journal of Medicine, 2026 · FDA iptacopan label

NefIgArd evaluated a targeted-release budesonide formulation against placebo in a different study framework. Its two-year report included an assessment of kidney function after a defined earlier treatment course. The presence of different drug mechanisms, eligibility criteria, background care and comparator arms limits numerical ranking across trials. A patient can be eligible for an option based on factors that are not captured by comparing two headline slope figures. Travere’s commercial exposure is to a treatment landscape with growing evidence and several distinct clinical and safety trade-offs. Lafayette et al., The Lancet, 2023 · Rovin et al., The Lancet, 2023

Atrasentan has a U.S. accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression under its label. The FDA states that slowing kidney function decline has yet to be established for that indication. The distinction between endpoints matters for how an investor characterizes competition. One can compare the labels and trial designs directly. A clinical head-to-head efficacy conclusion would require a different body of evidence. FDA atrasentan label

Atacicept adds another mechanism to the U.S. treatment landscape. FDA granted accelerated approval in July 2026 for reducing proteinuria in adults with primary IgA nephropathy at risk for disease progression. A subsequent Phase 3 publication reported the protocol-defined composite of kidney-disease progression and compared atacicept with placebo. The published analysis and the wording of the currently authorized indication provide different information. A commercial comparison should account for the distinct route of administration and labeled safety requirements as well as what each trial measured. FDA atacicept label · Barratt et al., New England Journal of Medicine, 2026

The FDA also granted accelerated approval to intravenous ravulizumab for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression. This adds a C5 inhibitor with a separate label and administration requirements. FDA Ultomiris October 2026 label, section 1.5

07 Additional sparsentan studies can refine specific questions

Travere reported completion of enrollment in SPARX, a study in people with recurrent IgA nephropathy or FSGS after kidney transplantation, with data anticipated in 2027. That setting differs from the main randomized trials that supported current U.S. indications. It involves a different prior treatment course and potential background therapy. A study in those patients can describe clinical observations and safety in that setting. Neither enrollment completion nor an expected reporting year expands the approved label. Travere Q3 exhibit, additional FILSPARI studies

The company is also starting a Phase 4 open-label single-arm study, SPARLIGHT, in a high-risk FSGS group. Its stated year-end goal concerns the first participant. The study can add detail about use and outcomes in a defined group, but changes seen during follow-up should be interpreted with the design. As in the underlying DUPLEX study, the endpoint measured and the population included determine the strength and reach of any inference. Travere Q3 exhibit, SPARLIGHT description · Rheault et al., New England Journal of Medicine, 2023

The October ASN presentation also included a biomarker analysis from PROTECT. Biomarkers linked to inflammatory or immune activity can help researchers interpret mechanisms or decide which hypothesis to test next. A change in a marker does not independently establish a clinical effect in an unstudied group. For the commercial outlook, the relevant evidence remains the approved population, the clinical outcome in that indication and the practical experience of prescribing and continuation. Travere ASN biomarker report · FDA FILSPARI label

SPARTAN studied sparsentan in 12 adults with newly diagnosed biopsy-confirmed IgA nephropathy and no use of an inhibitor of the renin-angiotensin system in the prior year. The published interim analysis reported a 68.8% fall in the urine protein-to-creatinine ratio at 24 weeks. Seven of the 12 participants had complete proteinuria remission at one or more visits in the interim analysis. The study was open label and single arm. It describes observations in an early treatment setting and has no same-study comparator. Its protocol and follow-up differ from the Phase 3 PROTECT comparison. Cheung et al., Kidney International Reports, 2026 · SPARTAN trial NCT04663204

08 Product demand, start forms and revenue have different timing

Travere reported 1,932 new patient start forms across the two kidney indications in the September quarter. A start form reflects activity in bringing a patient into the prescribing and distribution process. A form can precede an insurance decision, dispensing or actual initiation. Continuation on treatment and the net amount realized on each paid prescription matter for reported product sales. The quarterly count is therefore a measure of demand and enrollment activity with a different timing and denominator from net revenue. Travere Q3 exhibit · Travere Form 10-Q, commercialization and revenue recognition

Net product sales, U.S. dollars, millionsQ3 2026Q3 20259M 20269M 2025
FILSPARI200.19290.900446.422218.668
Tiopronin products20.00422.25059.61865.184
Total net product sales220.196113.150506.040283.852

FILSPARI represented just under 91% of September-quarter product sales. Tiopronin sales were lower than in the comparable quarter, so the portfolio growth came from the kidney drug. Net product sales are presented separately from revenue under licensing and collaboration arrangements. Investors tracking the commercial trajectory should compare product sales from the same reporting category and period. One-time license or milestone revenue can move total revenue even when the number of dispensed prescriptions changes little. Travere Form 10-Q, product sales table and license revenue

Travere increased commercial investment for both indications, including expanding its field force. This adds a cost before all potential accounts or patients convert to durable prescriptions. Whether that investment becomes more productive over time is a question for later sales and expenditure data. It can be useful to compare growth in product sales with changes in SG&A and planned commercialization spending, while keeping nonrecurring transaction items and clinical program investment separate. Travere Form 10-Q, management expense discussion

09 HARMONY tests an enzyme replacement in classical homocystinuria

Classical homocystinuria due to cystathionine beta-synthase deficiency is the setting for pegtibatinase, an investigational enzyme replacement. High total homocysteine is a biochemical feature measured in clinical studies. Earlier treatment strategies and background care remain relevant to understanding who entered those studies. In COMPOSE, investigators evaluated dose cohorts, safety and preliminary biochemical efficacy in adults and adolescents with elevated levels while receiving their existing care. Ficicioglu et al., Genetics in Medicine, 2025 · ClinicalTrials.gov COMPOSE NCT03406611

HARMONY is a randomized placebo-controlled Phase 3 study. Travere expects enrollment of about 70 participants aged 12 through 65 with screening plasma total homocysteine generally at or above 80 µM. The protocol allows up to 18 participants with a screening value of at least 50 µM and below 80 µM. The primary endpoint compares change from baseline in plasma total homocysteine averaged across weeks 6 through 12. A key secondary measure compares the change from baseline averaged across weeks 16, 20 and 24. These are prospectively defined measures under the study design. The November update targets initial results in the second half of 2027. HARMONY registry NCT06247085 · Travere Q3 exhibit, HARMONY design

A favorable value on the biochemical endpoint would be evidence for the effect measured in this study. Follow-up can clarify whether it persists, how often dosing is interrupted and whether adverse events affect tolerability. The expansion from early small cohorts to a randomized pivotal comparison is relevant because consistency and safety matter when estimating the outcome for a broader group. Regulatory review and any further evidence requirements would follow under the applicable process. Ficicioglu et al., Genetics in Medicine, 2025 · HARMONY trial design

10 Manufacturing is a distinct consideration in the pivotal program

Travere previously paused new enrollment in HARMONY in connection with scale-up delays. The current quarterly update says the study is enrolling. Resuming enrollment helps advance the clinical timeline. A program moving toward later development must also demonstrate that manufacturing and supply support the planned clinical work and any future regulatory package. The clinical readout and the work required to complete a filing are distinct operational milestones. Travere Form 10-Q, pegtibatinase development and manufacturing · Travere Q3 program update

HARMONY tests a metabolic intervention with its own population and safety measures. It does not use the kidney-function outcomes that distinguish the approved FILSPARI indications. The costs of pegtibatinase development cannot be estimated simply by applying a margin to the kidney product’s sales. Travere attributed a meaningful part of higher research expense to the study and manufacturing. Travere Form 10-Q, R&D expense and pipeline discussion

The company’s projected results window depends on completing enrollment and obtaining follow-up for the endpoint schedule. A clinical update would be more informative if it reports the progress of those steps and the extent to which planned analyses remain on schedule. Commercial contributions from the program would require additional evidence and decisions. Until then, the accounting effect of its development is primarily in research and development expense and related cash flows. HARMONY ClinicalTrials.gov record · Travere Form 10-Q

11 Civorebrutinib is a licensing commitment with clinical work ahead

Travere licensed rights to civorebrutinib from Everest Medicines and identified several immune-mediated kidney diseases for potential development, including primary membranous nephropathy, immune-mediated FSGS and minimal change disease. The company describes civorebrutinib as an investigational Bruton’s tyrosine kinase inhibitor. The product is a separate clinical proposition from sparsentan, even if some areas of study overlap in the broad category of glomerular disease. The November update identifies a planned U.S. investigational application by year-end as an upcoming company action. Travere Q3 SEC exhibit · Travere Form 10-Q, Everest agreement

Travere secured exclusive rights to develop, manufacture and commercialize the product in the United States and other markets outside Greater China and certain East and Southeast Asian countries. It paid $112.5 million up front in July. The agreement gives Everest the potential to receive up to $1.0 billion of additional development, regulatory and commercial milestones plus tiered royalties on net sales in the licensed territory ranging from a high single-digit rate to double-digit rates. The upfront payment is a transaction that occurred. The contingent totals describe possible payments that depend on future outcomes. The company and Everest also agreed to collaborate on aspects of clinical development and share costs for global trials. Travere Form 10-Q, license and collaboration note

The $113.115 million charged to acquired in-process R&D includes upfront consideration and direct costs. The accounting reflects an asset acquisition involving development work for which the company did not identify an alternative future use. The full expense was recognized at closing, while the related cash payment was reported as an investing outflow. This separation is central to reading the quarter: the operating income figure includes the expense, and the cash-flow classification places the acquisition payment outside operating cash flow. Travere Form 10-Q, IPR&D and cash-flow statements

An eventual treatment study in primary membranous nephropathy would need to define both the population and the evidence required to distinguish immune effects from changes in proteinuria. The U.S. investigational application Travere describes would allow the program to move toward testing under the proposed plan if the relevant requirements are met. The planned application and any later controlled result sit at different stages of development. Spending and milestones in the licensing agreement can follow those stages on their own schedule. Travere investor update, civorebrutinib program · Travere Form 10-Q, Everest agreement

12 Product revenue and collaboration revenue moved in opposite directions

Travere’s third-quarter net product sales were $220.196 million, up from $113.150 million. License and collaboration revenue dropped to $4.367 million from $51.709 million. Higher product sales more than offset that difference, but the change in total revenue was smaller than the change in sales of products alone. Year-over-year comparisons using revenue growth need to account for what was recognized in the prior period. Travere Form 10-Q, revenue data

The year-earlier quarter included a $40 million market access milestone linked to CSL Vifor’s agreement. Travere reported collaboration revenue under the CSL Vifor agreement of about $4.1 million in the latest quarter compared with $42.4 million a year earlier. A separate $9.3 million of license revenue from relinquishing the buyout right under the Chugai license also contributed to the 2025 comparison. The geographic partner arrangement has a different economic structure from selling FILSPARI through the U.S. channel. A royalty or market access milestone can be material, and the same milestone cannot recur every period. The revenue category and the timing of receipt should be considered separately. Travere Form 10-Q, CSL Vifor license agreement and financial results

The $10 million milestone from Mirum was recognized in discontinued operations in the 2026 quarter. The filing says it was an account receivable at September 30. The related discontinued-operations income was $8.7 million after tax in Q3 and $8.2 million through nine months. This arose from the prior sale of a business and reflects conditions tied to the buyer’s sales. Its appearance as income from discontinued operations differs from recognizing license revenue in continuing operations. Later cash collection also differs from the accounting date on which the milestone was recognized. Travere Form 10-Q, discontinued operations and accounts receivable notes

13 The income statement includes ongoing costs and the deal expense

Research and development and selling, general and administrative expenses both grew in the quarter. The transaction expense also entered the operating statement. As a result, reported operating income in the prior-year quarter became a loss in the current quarter despite greater product revenue. This makes the cost and contribution of ongoing activity important to interpreting the change. The nine-month period includes another item below operations, an inducement expense relating to a debt transaction. Travere Form 10-Q, statements of operations and management discussion

U.S. dollars, millionsQ3 2026Q3 20259M 20269M 2025
Net product sales220.196113.150506.040283.852
License and collaboration revenue4.36751.70915.30577.187
Total revenue224.563164.859521.345361.039
Cost of goods sold2.8671.5856.9917.786
Research and development70.30451.890187.680148.141
Selling, general and administrative98.41471.046274.779194.041
Royalty expense7.96815.40739.84641.467
Acquired in-process R&D113.1150113.1150
Total operating expenses292.668139.928622.411391.435
Operating income or loss(68.105)24.931(101.066)(30.396)
Interest income3.7043.0479.64310.129
Interest expense(2.140)(2.751)(6.575)(8.452)
Other income or expense, net(0.391)0.487(0.650)0.511
Inducement expense00(40.008)0
Total other income or expense1.1730.783(37.590)2.188
Continuing operations before taxes(66.932)25.714(138.656)(28.208)
Tax benefit or expense on continuing operations5.895(0.008)6.220(0.067)
Continuing operations, after tax(61.037)25.706(132.436)(28.275)
Discontinued operations, after tax8.70008.2000
Net income or loss(52.337)25.706(124.236)(28.275)

Adding back only the $113.115 million acquisition expense to the reported quarterly operating loss would produce operating income of $45.010 million. That single-item Merlintrader calculation describes the size of the expense relative to operating income. It is not a normalized earnings forecast and leaves all other items, including ordinary R&D, reported royalties and collaboration revenue, as filed. It also says nothing by itself about the ongoing cash required to develop what Travere acquired. Travere Form 10-Q, consolidated statements and acquisition disclosure

14 Royalty expense and payments can move on different schedules

Travere treats some royalties and milestones as capitalized intangible assets and amortizes the balance, while it expenses some royalty payments directly. The 10-Q reports $37.408 million of royalties and milestones capitalized during the quarter and $83.831 million during the first nine months. Those amounts differ from current-period royalty expense. For comparability, the company reclassified 2025 royalty expense of $15.4 million for Q3 and $41.5 million for nine months out of SG&A and into a separate line. Understanding which costs are capitalized is important when looking at the gap between revenue, cost of goods and cash outlays. Travere Form 10-Q, royalty accounting and related schedules

The company disclosed that amortization of its Thiola-related intangible finished during the first quarter of 2026. It subsequently began expensing the related royalty payments during the period incurred. That change affects comparison of expense between quarters and is separate from any change in the number of tiopronin prescriptions. The company also remains subject to the disclosed minimum or sales-based provisions on that product. Travere Form 10-Q, notes on intangible assets and Thiola royalties

A cash-flow analysis also needs the acquisition of intangible assets in investing activities and the movement in accrued royalties and other expenses. Profit may include amortization of earlier spending while cash payments include costs that will be recognized in later periods. The fact that a given quarter has strong net product sales says little about how quickly the associated contractual costs are paid. Reading the royalty schedule and cash-flow statement together shows when the costs affect different measures. Travere Form 10-Q, intangible assets and condensed statement of cash flows

15 The cash balance includes securities, while notes remain a separate obligation

Travere reported $123.542 million in cash and equivalents and $348.276 million in marketable debt securities at September 30. Together they represent $471.818 million of liquid resources at the balance sheet date. The balance sheet separately reports convertible debt, operating liabilities and the obligations that accompany the commercial and clinical programs. The headline resource figure and the value of the outstanding notes describe different sides of the balance sheet. Travere Form 10-Q, consolidated balance sheet and debt note

U.S. dollars, millionsSep. 30, 2026Dec. 31, 2025
Cash and cash equivalents123.54293.035
Marketable debt securities348.276229.761
Combined cash, equivalents and marketable debt securities471.818322.796
Total current assets633.446437.565
Total current liabilities210.912159.904
Convertible debt, carrying amount603.510311.724
Total liabilities825.645490.363
Total stockholders’ equity22.584114.828
Total assets848.229605.191

The September current assets less current liabilities amount to $422.534 million. That includes receivables, inventory and other current assets in addition to cash and marketable securities. It also excludes the longer-term carrying value of the convertible notes as classified in the filing. For a liquidity assessment, the composition and timing matter. Receivables help when collected and some obligations fall due on particular schedules. The level of liquid resources is more useful when read with how operations and financing changed them. Travere Form 10-Q, balance sheet and cash flow

16 Convertible refinancing changed the timing and mix of obligations

Travere issued $525 million in principal amount of 0.50% convertible senior notes due May 2032. It repurchased part of its 2.25% convertible senior notes due in 2029 and reported $94.875 million of remaining principal in that series at quarter end. Combined principal was $619.875 million, while the carrying amount was $603.510 million after unamortized issuance costs. A balance sheet carrying value measures an accounting amount. Cash settlement or conversion depends on the terms and what happens over the life of each series. Travere Form 10-Q, Note 9 and financing activities

Travere recorded $350.885 million in cash outflow to repurchase 2029 notes, including the premium as presented in the cash-flow statement. It classified the transaction as an induced conversion under the accounting guidance discussed in the notes, recording $40.008 million of inducement expense during the first nine months. The expense and the full repurchase payment are separate measurements. Paying a premium to retire an obligation can reduce cash today and change the maturity profile and interest obligations later. Travere Form 10-Q, convertible notes and cash flow

The new notes carry a lower coupon than the outstanding 2029 notes. The total principal amount increased compared with the prior year end. Conversion could change the amount settled in cash or the number of shares delivered under terms of the instruments. Tracking basic shares outstanding, debt principal and potential conversion exposure separately gives a more accurate view of capital structure than treating outstanding notes as if fully repaid or converted today. Travere Form 10-Q, convertible senior notes, financing and per-share disclosures

17 Positive operating cash flow did not eliminate investment outflows

Continuing operations provided $92.409 million of cash in the first nine months of 2026, and discontinued operations provided an additional $23.500 million. The comparable 2025 period used $22.894 million in operating activities. The consolidated operating cash-flow line includes working-capital effects and adds back the $113.115 million acquired research charge before the acquisition payment appears under investing. That is why the operating cash figure and the net loss move differently. Travere Form 10-Q, consolidated statements of cash flows

U.S. dollars, millions9M 20269M 2025
Beginning cash and equivalents93.03558.535
Operating cash flow, continuing operations92.409(22.894)
Operating cash flow, discontinued operations23.5000
Total operating cash flow115.909(22.894)
Investing cash flow(304.364)132.731
Financing cash flow219.009(60.146)
Currency effects(0.047)2.704
Change in cash and equivalents30.50752.395
Ending cash and equivalents123.542110.930

Purchases of marketable securities exceeded their proceeds from sales and maturities in 2026. Acquired IPR&D and purchases of other intangible assets were additional large investing uses. Purchases of securities cause cash to move into investments held on the balance sheet. Acquisitions and payments for intangible assets are separate uses. Financing cash flow in the period included the new note proceeds, costs, the repurchase and proceeds from employee equity activity. Travere Form 10-Q, statements of cash flows and management discussion

The operating reconciliation also shows an increase in receivables and an increase in accrued expenses. Growth in sales can add amounts owed by customers, and recognized expense can precede payment. Those offsets can matter when deciding how much cash a stronger commercial quarter produced. The sustainable cash movement depends on later collections and settlement of operating obligations, alongside spending on development and licensing. Travere Form 10-Q, changes in operating assets and liabilities

The current 10-Q reclassified $24.5 million of first-half operating cash receipts from continuing to discontinued operations. Corrected first-half continuing operating cash flow was negative $6.8 million, and discontinued operations generated $24.5 million. The reclassification left total operating cash flow unchanged. Mirum paid the earlier $25 million milestone in April. Travere Form 10-Q, Notes 16 and 18

18 International partnerships do not mirror the U.S. sales model

The agreement with CSL Vifor covers specified territories outside the United States. The partner is responsible for commercialization under the agreement. Travere can receive royalties tied to sales and may receive regulatory, access and sales milestones as defined in the license. The terms make regulatory and reimbursement decisions in individual markets relevant to Travere’s future cash flows. Product availability and revenue recognition in the United States remain separate measures. Travere Form 10-Q, CSL Vifor license agreement

The agreement initially signed with Renalys covers development and commercialization in Japan and specified other Asian territories. The filing identifies the current relationship as the Chugai license agreement following Renalys’s merger into Chugai. The reported amount eligible under the agreement includes potential regulatory, development and sales milestones of up to $120 million and separate royalties. Chugai submitted a Japanese application for sparsentan in IgA nephropathy on June 19, 2026, based on PROTECT and a Japanese Phase 3 study. Chugai application announcement Regional rights, program progress and future partner sales have to be tracked on their own terms. Travere Form 10-Q, Chugai license and Japan program discussion

Different contracts can cause revenue to arrive unevenly. A one-time payment recognizes satisfaction of a defined condition, while a partner royalty depends on sales over time. Clinical data, market access and an eventual cash receipt can fall in different periods. The domestic product business can keep expanding while reported licensing revenue falls against a quarter with a milestone. That distinction is relevant when interpreting both aggregate revenue and the timing of cash contributions. Travere Form 10-Q, revenue recognition and geographic licenses

19 Equity, note conversion and a leadership change belong on separate timelines

The 10-Q reports 95,673,465 common shares outstanding at September 30 and 95,992,155 on October 28. The initial conversion rate for the 2032 notes is 15.4078 shares per $1,000 principal. The terms allow the company to settle conversions with cash, shares or a combination, subject to the applicable provisions. An instrument can therefore have potential equity exposure without every possible conversion share already being included in common shares outstanding. Travere Form 10-Q, cover, stockholders’ equity and debt terms

A Schedule 13G amendment filed November 16 reported 6,810,705 shares beneficially owned by Bank of America Corporation, or 7.1%, as of September 30. The ownership statement reflects the reporting party’s disclosure at that date and is distinct from total shares outstanding or potential shares issuable on note conversion. November 16 Schedule 13G/A

FMR LLC separately disclosed beneficial ownership of approximately 5.71 million shares, or 6.1%, as of September 30. November 5 Schedule 13G/A

The company reported a planned transition to a new president and chief executive officer effective December 1. The announcement sets out the handover and an advisory period after the change. The expense of the transition is another reason to read upcoming SG&A reports with their disclosures rather than assume that all changes come from the FILSPARI field force. The quarterly notes report $4.4 million of compensation expense through September and expect a further $26.9 million to be recognized in the fourth quarter from the arrangement described. Travere September 21 Form 8-K · Travere Form 10-Q, stock compensation note

The available capital and the way it is allocated influence the company’s ability to invest through changes in leadership and commercial focus. A strategic program can be attractive and also require significant cash before it contributes sales. The lower coupon on one debt series, the settlement terms on convertible debt and operating receipts matter in different ways for that decision. Investors will have more evidence as the company reports how it funds additional studies and how product cash generation changes alongside those commitments. Travere Form 10-Q, commitments, financing and management discussion

20 The next measurements that can change the analysis

For FILSPARI, the path from the approved indication to recurring revenue includes medical eligibility, prescribing, dispensing and continuation. A consistent increase in aggregate net product sales accompanied by a stronger cash contribution would give evidence of commercial progress. Separate disclosure of the mix between IgA nephropathy and FSGS could also show which group is driving growth. A further label change, available only through regulatory action, would require evaluating the evidence and patient population on its own terms. FDA FILSPARI label · Travere Q3 exhibit

For HARMONY, enrollment and follow-up determine when the specified biochemical measures can be reported. For civorebrutinib, an investigational submission and a defined study design would clarify the initial plan in the United States. The size of the license commitment and the expense recorded at closing do not establish that any proposed study will succeed. Those amounts affect capital allocation today, while the evidence develops over time. HARMONY trial registry · Travere quarterly update and planned milestones

For reported earnings, the next comparisons benefit from keeping product sales, collaboration revenue, acquired research expense, royalties and discontinued operations distinct. The expense or capitalization associated with a particular asset affects the statements at different times from prescriptions sold in the quarter. On the cash side, investing outflows for rights and financing transactions can move the balance substantially even as the underlying product business changes in the opposite direction. The signed filings disclose the cash and accounting effects separately. Travere Form 10-Q, consolidated financial statements and notes

Merlintrader Health Score · $TVTX

3.45out of 5
Balance sheet and runway · 30%3.5

Liquidity rose and continuing operations generated cash over nine months, while convertible principal and commitments remain material. Balance sheet.

Catalyst · 30%3.5

FILSPARI launch metrics and HARMONY follow-up provide measurable milestones. Calendar.

Dilution · 20%3.0

The two convertible note series have contingent settlement and equity implications. Convertible notes.

Liquidity · 10%3.5

Travere has Nasdaq-listed common shares and a separate convertible capital structure. Capital structure.

Execution · 10%4.0

Strong FILSPARI sales growth supports the commercial base. HARMONY and the licensing program require further execution. Product sales.

Assessed November 20, 2026. Merlintrader calculation: 3.5 × 30% + 3.5 × 30% + 3.0 × 20% + 3.5 × 10% + 4.0 × 10% = 3.45 out of 5.

Red flags to track

  • FILSPARI accounts for most product sales, making prescribing, reimbursement and continuation material.
  • The FSGS label concerns reduction of proteinuria in people without nephrotic syndrome, with the age limit specified by the FDA.
  • HARMONY and civorebrutinib remain investigational. Their dates are company expectations.
  • Product sales, license payments and discontinued operations can affect results at different times.
  • Royalty accounting and acquired research expense can create differences between operating income and cash outlays.
  • Convertible notes carry obligations and potential equity exposure under their terms.

TVTX Stock FAQ: Travere Therapeutics Questions Answered

What are the approved U.S. FILSPARI uses?

The label covers slowing kidney function decline in adults with primary IgA nephropathy at risk of disease progression, and reducing proteinuria in people aged eight and older with FSGS without nephrotic syndrome. FDA label

What did DUPLEX show?

The overall study found a greater proportion of proteinuria partial remission at week 36 with sparsentan. Its final comparison did not show a significant difference on the primary eGFR slope endpoint. Rheault et al., New England Journal of Medicine, 2023

How much did FILSPARI contribute to the quarter?

Travere reported U.S. FILSPARI net product sales of $200.192 million for the quarter ended September 30, up from $90.900 million a year earlier. Travere Form 10-Q, net product sales

Are patient start forms the same as paid prescriptions?

A form measures activity in bringing patients into the start process. Net product sales reflect the transactions recognized under the company’s accounting policy. Travere Q3 exhibit · Travere Form 10-Q

What is the primary HARMONY endpoint?

The study compares change from baseline in plasma total homocysteine averaged over weeks 6 to 12 with pegtibatinase versus placebo. ClinicalTrials.gov NCT06247085

Why was the Everest expense larger than the upfront payment?

The $113.115 million charge includes upfront consideration and direct transaction costs. The agreement required a $112.5 million upfront payment. Travere Form 10-Q, agreement and accounting treatment

How much liquid capital and convertible debt did Travere report?

Cash, equivalents and marketable debt securities totaled $471.818 million at September 30. The convertible notes’ combined carrying amount was $603.510 million. Travere Form 10-Q, balance sheet and notes

Which milestone was included in discontinued operations?

Travere recognized a $10 million milestone from Mirum tied to sales under a previous asset transaction. The amount was in receivables at September 30. Travere Form 10-Q, discontinued operations

Sources and scientific literature

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $TVTX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biopharmaceutical companies face clinical, regulatory, manufacturing, reimbursement, commercialization and financing risks, including dilution. Investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.